세계의 제약 여과 시장 : 제품별, 기술별, 용도별, 운영 규모별 - 예측(-2029년)

The global pharmaceutical filtration market is projected to reach USD 20.97 billion by 2029 from USD 13.31 billion in 2024, at a CAGR of 9.5% during the forecast period of 2024 to 2029. The growth of the oral proteins and peptides market has been significantly driven by increasing R&D investment by key players for the development biopharmaceutical drugs and growing adoption of continuous manufacturing process . However, requirement of high capital investments for new production facilities are restraining market growth.

"The sterile filtration segment accounted for the largest share by type in 2023."

Sterile filtration segment accounted for largest share of the market due to increasing focus on development of advanced therapies and rising focus on biomedical research. These increasing focus on biomedical research drives the demand for sterile filtration technologies to maintain sterile conditions and prevent cross-contamination for the production and manufacturing of biopharmaceuticals. Additionally, increasing approval biologics and biosimilars is driving the need of sterile filtration. Moreover, increasing vaccine production for the treatments of several diseases such as infectious diseases is promoting the segment growth in pharmaceutical filtration market.

"The US has continued to dominate the pharmaceutical filtration market during the forecast period of 2024-2029."

The US is the world's largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Driven by the growing patient population suffering from infectious disease, increasing biopharmaceuticals' importance, and the necessity of safe and high-quality products in the healthcare sector, growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include, Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), 3M Company (US).

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

List of key Companies Profiled in the Report:

Danaher Corporation (US), Merck KGaA (Germany), Sartorius AG (Germany), 3M Company (US), Repligen Corporation (US), Parker Hannifin Corporation (US), Eaton Corporation plc (Ireland), Thermo Fisher Scientific, Inc. (US), Donaldson Company, Inc. (US), Porvair PLC (UK), Alfa Laval Corporate AB (Sweden), Corning Incorporated (US), MANN+HUMMEL (Germany), Saint-Gobain (France), STERIS plc (US), Meissner Filtration Products, Inc. (US), Amazon Filters Ltd. (UK), Graver Technologies, LLC. (US), MMS AG (Switzerland), ErtelAlsop (US), Kasag Swiss AG (Switzerland), Freudenberg Filtration Technologies SE & Co. KG (Germany), Cole-Parmer Instrument Company, LLC (US), Filtrox AG (Switzerland), Membrane Solutions (US).

Research Coverage:

This research report categorizes the oral proteins and peptides market by Product )Consumables (Filters (Membrane Filters, Depth Filters, Air Filter, Virus Filter, and Other Filters) and Other Consumables (Filtration Assemblies, Filter Holders, and Filtration Acccessories) and Systems (Single-Use Systems and Reuseable Systems)), by Technique (Microfiltration, Ultrafiltration, Nanofiltration, and Other Techniques), by Type (Sterile Filtration and Non-Sterile Filtration) by Application (Final Product Processing (Active Pharmaceutical Ingredient Filtration, Protein Purification, Vaccines and Antibody Processing, Formulation and Filling Solutions, and Viral Clearance), Raw Material Filtration (Media Buffer filtration, Pre-Filtration, and Bioburden Testing), Cell Separation, Water Purification, and Air Purification) and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oral proteins and peptides market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the oral proteins and peptides market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmaceutical filtration market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Growing pharmaceutical industry, Rising R&D spending in pharmaceutical and biotechnology industries, Increasing adoption of single-use technologies, Increasing purity requirement in pharmaceutical and biotechnology manufacturing, and Adoption of a continuous manufacturing process), restraints (Membrane fouling issues, Requirement of high capital investment for new production facilities, and Technological limitations), opportunities (Growth opportunities in emerging economies, Advances in nanofiber technology, and Growing need for high-efficiency filters for vaccine production), and Challenges (Increased cost and reduced speed and yield of filters, Survival of small players and new entrants, and Stringent regulatory compliance).
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the pharmaceutical filtration market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the pharmaceutical filtration market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the pharmaceutical filtration market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 INCLUSIONS & EXCLUSIONS
  • 1.3.2 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 GLOBAL MARKET ESTIMATION
  • 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PHARMACEUTICAL FILTRATION MARKET
• 4.2 NORTH AMERICA: PHARMACEUTICAL FILTRATION MARKET, BY END USER AND COUNTRY, 2023
• 4.3 PHARMACEUTICAL FILTRATION MARKET, BY PRODUCT, 2023
• 4.4 PHARMACEUTICAL FILTRATION MARKET, BY END USER, 2023
• 4.5 PHARMACEUTICAL FILTRATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing pharmaceutical industry
    • 5.2.1.2 Rising R&D spending in pharmaceutical and biotechnology industries
    • 5.2.1.3 Increasing adoption of single-use technologies
    • 5.2.1.4 Increasing purity requirement in pharmaceutical and biotechnology manufacturing
    • 5.2.1.5 Adoption of continuous manufacturing process
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Membrane fouling and breakage issues
    • 5.2.2.2 High capital investments required for new production facilities
    • 5.2.2.3 Technological limitations
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth opportunities in emerging economies
    • 5.2.3.2 Advances in nanofiber technology
    • 5.2.3.3 Growing need for high-efficiency filters for vaccine production
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Increased cost and reduced speed and yield of filters
    • 5.2.4.2 Survival of small players and new entrants
    • 5.2.4.3 Stringent regulatory compliance
• 5.3 TECHNOLOGY ANALYSIS
  • 5.3.1 KEY TECHNOLOGIES
    • 5.3.1.1 Microfiltration
    • 5.3.1.2 Ultrafiltration
    • 5.3.1.3 Nanofiltration
  • 5.3.2 COMPLEMENTARY TECHNOLOGIES
    • 5.3.2.1 Single-Use Technology
    • 5.3.2.2 Electrospun Microfibers
    • 5.3.2.3 Photocatalytic Filtration
  • 5.3.3 ADJACENT TECHNOLOGIES
    • 5.3.3.1 Chromatography
    • 5.3.3.2 Centrifugation
    • 5.3.3.3 Microfluidics
• 5.4 SUPPLY CHAIN ANALYSIS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 PRICING ANALYSIS
  • 5.6.1 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY KEY PLAYERS, 2021-2023
  • 5.6.2 AVERAGE SELLING PRICE OF KEY PRODUCTS, BY REGION, 2023
• 5.7 ECOSYSTEM ANALYSIS
  • 5.7.1 RAW MATERIAL VENDORS IN PHARMACEUTICAL FILTRATION MARKET
  • 5.7.2 PRODUCT VENDORS IN PHARMACEUTICAL FILTRATION MARKET
  • 5.7.3 END USERS IN PHARMACEUTICAL FILTRATION MARKET
  • 5.7.4 REGULATORY BODIES IN PHARMACEUTICAL FILTRATION MARKET
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.9 PATENT ANALYSIS
  • 5.9.1 PATENT METHODOLOGY
  • 5.9.2 PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
• 5.10 KEY CONFERENCES & EVENTS
• 5.11 REGULATORY LANDSCAPE
  • 5.11.1 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS IN DIFFERENT REGIONS/COUNTRIES
  • 5.11.2 REGULATORY FRAMEWORK
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 THREAT OF NEW ENTRANTS
  • 5.12.2 THREAT OF SUBSTITUTES
  • 5.12.3 BARGAINING POWER OF BUYERS
  • 5.12.4 BARGAINING POWER OF SUPPLIERS
  • 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 ROLE OF STAKEHOLDER IN BUYING PROCESS
  • 5.13.3 BUYING CRITERIA FOR PHARMACEUTICAL FILTRATION MARKET
• 5.14 CASE STUDY ANALYSIS
  • 5.14.1 COST SAVING/OPTIMIZATION
  • 5.14.2 SUPPLY CHAIN SIMPLIFICATION
  • 5.14.3 COST SAVING AND SYSTEM OPTIMIZATION
  • 5.14.4 INTERMITTENT PREMATURE FILTER FOULING SOLVED
• 5.15 INVESTMENT/FUNDING SCENARIO
• 5.16 TRADE DATA ANALYSIS
• 5.17 IMPACT OF AI ON PHARMACEUTICAL FILTRATION MARKET

6 PHARMACEUTICAL FILTRATION MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 FILTERS
    • 6.2.1.1 Membrane Filters
      • 6.2.1.1.1 Polyethersulfone (PES)
        • 6.2.1.1.1.1 Wide use of hydrophilic PES membranes in sterilizing applications to drive growth
      • 6.2.1.1.2 Polyvinylidene difluoride (PVDF)
        • 6.2.1.1.2.1 Nontoxic nature to increase demand for PVDF filters
      • 6.2.1.1.3 Nylon
        • 6.2.1.1.3.1 Increased endotoxin adsorption capacity of nylon filters to drive growth
      • 6.2.1.1.4 Polytetrafluoroethylene (PTFE)
        • 6.2.1.1.4.1 PTFE membrane filters offer retention of ratings as fine as 0.01μ
      • 6.2.1.1.5 Mixed cellulose ester & cellulose acetate (MCE & CA)
        • 6.2.1.1.5.1 Growing analytical and research applications to drive market
      • 6.2.1.1.6 Polycarbonate track-etched (PCTE)
        • 6.2.1.1.6.1 Wide use in cell biology and analytical testing applications
      • 6.2.1.1.7 Other materials
    • 6.2.1.2 Depth filters
      • 6.2.1.2.1 Diatomaceous earth
        • 6.2.1.2.1.1 Increased use in biotechnology industry for cell clarification
      • 6.2.1.2.2 Cellulose
        • 6.2.1.2.2.1 Cost-effectiveness of cellulose-based depth filters to drive growth
      • 6.2.1.2.3 Activated carbon
        • 6.2.1.2.3.1 Reliable and cost-effective activated carbon filters supporting pharmaceutical manufacturing operations
      • 6.2.1.2.4 Perlite
        • 6.2.1.2.4.1 Lower density of perlite provides more purity than diatomaceous earth
      • 6.2.1.2.5 Other depth filter media
    • 6.2.1.3 Air filters
    • 6.2.1.4 Virus filters
    • 6.2.1.5 Other filters
  • 6.2.2 OTHER CONSUMABLES
    • 6.2.2.1 FILTRATION ASSEMBLIES
      • 6.2.2.1.1 Microfiltration assemblies
        • 6.2.2.1.1.1 Growing demand for high-quality products to support segment growth
      • 6.2.2.1.2 Ultrafiltration assemblies
        • 6.2.2.1.2.1 Stringent regulatory requirements likely to support segment growth
      • 6.2.2.1.3 Nanofiltration assemblies
        • 6.2.2.1.3.1 Increasing demand for high-purity biopharmaceuticals to propel segment growth
      • 6.2.2.1.4 Other filtration assemblies
  • 6.2.3 FILTER HOLDERS
    • 6.2.3.1 Filter holders provide structural support to membrane filters
  • 6.2.4 FILTRATION ACCESSORIES
    • 6.2.4.1 Increasing adoption of pharmaceutical filtration products to support growth
• 6.3 SYSTEMS
  • 6.3.1 SINGLE-USE SYSTEMS
    • 6.3.1.1 Reduced need for product validation and minimized cross-contamination risk to boost adoption
  • 6.3.2 REUSABLE SYSTEMS
    • 6.3.2.1 Reusable systems widely used for large-scale manufacturing

7 PHARMACEUTICAL FILTRATION MARKET, BY TECHNIQUE

• 7.1 INTRODUCTION
• 7.2 MICROFILTRATION
  • 7.2.1 INCREASED ADOPTION OF MICROFILTRATION TO PROPEL MARKET GROWTH
• 7.3 ULTRAFILTRATION
  • 7.3.1 ADOPTION OF FINE FILTRATION TECHNIQUES TO DRIVE GROWTH
• 7.4 NANOFILTRATION
  • 7.4.1 RISING DEMAND IN BIOTECHNOLOGY INDUSTRY TO SUPPORT MARKET GROWTH
• 7.5 OTHER TECHNIQUES

8 PHARMACEUTICAL FILTRATION MARKET, BY TYPE

• 8.1 INTRODUCTION
• 8.2 STERILE FILTRATION
  • 8.2.1 ADVANTAGES OF STERILE FILTERS OVER NON-STERILE FILTERS TO DRIVE GROWTH
• 8.3 NON-STERILE FILTRATION
  • 8.3.1 GROWTH IN PHARMA R&D ACTIVITIES TO PROMOTE MARKET GROWTH

9 PHARMACEUTICAL FILTRATION MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 FINAL PRODUCT PROCESSING
  • 9.2.1 ACTIVE PHARMACEUTICAL INGREDIENT (API) FILTRATION
    • 9.2.1.1 Continuous requirement for API filtration
  • 9.2.2 PROTEIN PURIFICATION
    • 9.2.2.1 Recent advancements in protein therapeutic drugs
  • 9.2.3 VACCINE AND ANTIBODY PROCESSING
    • 9.2.3.1 Development of vaccines for viral diseases
  • 9.2.4 FORMULATION AND FILLING SOLUTIONS
    • 9.2.4.1 Demand for aseptic filling and bioburden reduction
  • 9.2.5 VIRAL CLEARANCE
    • 9.2.5.1 Growing development of therapeutic monoclonal antibodies
• 9.3 RAW MATERIAL FILTRATION
  • 9.3.1 MEDIA BUFFER FILTRATION
    • 9.3.1.1 Growth in manufacturing of biopharmaceuticals to drive market
  • 9.3.2 PREFILTRATION
    • 9.3.2.1 High demand due to membrane fouling issues
  • 9.3.3 BIOBURDEN TESTING
    • 9.3.3.1 Strict quality control of biopharmaceuticals to drive market
• 9.4 CELL SEPARATION
  • 9.4.1 GROWTH IN PERSONALIZED MEDICINE TO PROPEL MARKET
• 9.5 WATER PURIFICATION
  • 9.5.1 GROWTH IN GERIATRIC POPULATION TO DRIVE MARKET
• 9.6 AIR PURIFICATION
  • 9.6.1 INCREASING ADOPTION OF GOOD MANUFACTURING PRACTICES TO DRIVE MARKET

10 PHARMACEUTICAL FILTRATION MARKET, BY SCALE OF OPERATION

• 10.1 INTRODUCTION
• 10.2 MANUFACTURING-SCALE OPERATION
  • 10.2.1 GROWTH IN BIOLOGICS AND BIOSIMILAR MANUFACTURING TO DRIVE MARKET
• 10.3 PILOT-SCALE OPERATION
  • 10.3.1 INCREASED OUTSOURCING TO DRIVE MARKET GROWTH
• 10.4 R&D-SCALE OPERATION
  • 10.4.1 INCREASING INVESTMENTS IN R&D OF BIOLOGICS TO PROPEL GROWTH

11 PHARMACEUTICAL FILTRATION MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
  • 11.2.1 GROWING BIOLOGICS PRODUCTION TO DRIVE DEMAND
• 11.3 CMOS & CROS
  • 11.3.1 INCREASING OUTSOURCING OF R&D SERVICES TO SUPPORT MARKET GROWTH
• 11.4 ACADEMIC & RESEARCH INSTITUTES
  • 11.4.1 GROWING PHARMA-ACADEMIA COLLABORATIONS TO DRIVE ADOPTION

12 PHARMACEUTICAL FILTRATION MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 NORTH AMERICA: MACROECONOMIC ANALYSIS
  • 12.2.2 US
    • 12.2.2.1 US to dominate North American market during forecast period
  • 12.2.3 CANADA
    • 12.2.3.1 Growing government support for expanding biologics manufacturing facilities to support market
• 12.3 EUROPE
  • 12.3.1 EUROPE: MACROECONOMIC ANALYSIS
  • 12.3.2 GERMANY
    • 12.3.2.1 Growing pharmaceutical R&D and manufacturing to drive market
  • 12.3.3 UK
    • 12.3.3.1 Growing awareness of quality of drugs increasing uptake of filtration products in drug discovery labs
  • 12.3.4 FRANCE
    • 12.3.4.1 Government investment in pharmaceutical industry to drive growth
  • 12.3.5 ITALY
    • 12.3.5.1 Investment in biotechnology R&D to boost market growth
  • 12.3.6 SPAIN
    • 12.3.6.1 Expansion of biomanufacturing facilities to support market
  • 12.3.7 SWITZERLAND
    • 12.3.7.1 Presence of key pharmaceutical and biopharmaceutical companies to support market
  • 12.3.8 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 ASIA PACIFIC: MACROECONOMIC ANALYSIS
  • 12.4.2 CHINA
    • 12.4.2.1 Improving drug development activities to drive market
  • 12.4.3 JAPAN
    • 12.4.3.1 Stringent regulatory guidelines to create need for advanced filtration products
  • 12.4.4 INDIA
    • 12.4.4.1 Favorable scenario for foreign direct investment to favor market growth
  • 12.4.5 SOUTH KOREA
    • 12.4.5.1 Increased export of drugs to support market growth
  • 12.4.6 AUSTRALIA
    • 12.4.6.1 Increasing demand for innovative filtration solutions to propel market
  • 12.4.7 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 LATIN AMERICA: MACROECONOMIC ANALYSIS
  • 12.5.2 BRAZIL
    • 12.5.2.1 Increased government investments in pharmaceutical R&D to drive market
  • 12.5.3 MEXICO
    • 12.5.3.1 Rising demand for chronic disease treatment to support market growth
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST
  • 12.6.1 MIDDLE EAST: MACROECONOMIC ANALYSIS
  • 12.6.2 GCC COUNTRIES
  • 12.6.3 SAUDI ARABIA
    • 12.6.3.1 Growing healthcare expenditure to boost market growth
  • 12.6.4 UAE
    • 12.6.4.1 Adoption of more efficient and precise filtration processes to aid market growth
  • 12.6.5 REST OF GCC COUNTRIES
  • 12.6.6 REST OF MIDDLE EAST
• 12.7 AFRICA
  • 12.7.1 AFRICA: MACROECONOMIC ANALYSIS

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022-2024
• 13.3 REVENUE SHARE ANALYSIS, 2019-2023
• 13.4 MARKET SHARE ANALYSIS, 2023
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Product footprint
    • 13.5.5.3 Technique footprint
    • 13.5.5.4 Application footprint
    • 13.5.5.5 Region footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
• 13.7 COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2023
• 13.8 VALUATION AND FINANCIAL METRICS OF PHARMACEUTICAL FILTRATION VENDORS
• 13.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 13.9.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT
• 13.10 COMPETITIVE SCENARIO
  • 13.10.1 PRODUCT LAUNCHES
  • 13.10.2 DEALS
  • 13.10.3 EXPANSIONS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 DANAHER CORPORATION
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product launches
      • 14.1.1.3.2 Deals
      • 14.1.1.3.3 Expansions
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses and competitive threats
  • 14.1.2 MERCK KGAA
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Expansions
      • 14.1.2.3.2 Other developments
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 SARTORIUS AG
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches
      • 14.1.3.3.2 Deals
      • 14.1.3.3.3 Expansions
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 3M COMPANY
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches
      • 14.1.4.3.2 Deals
      • 14.1.4.3.3 Other developments
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Key strengths
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses and competitive threats
  • 14.1.5 REPLIGEN CORPORATION
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches
      • 14.1.5.3.2 Deals
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Key strengths
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 PARKER HANNIFIN CORPORATION
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
  • 14.1.7 EATON CORPORATION PLC
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Product launches
  • 14.1.8 THERMO FISHER SCIENTIFIC, INC.
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Expansions
  • 14.1.9 DONALDSON COMPANY, INC.
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Deals
      • 14.1.9.3.2 Expansions
  • 14.1.10 PORVAIR PLC
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Product launches
  • 14.1.11 ALFA LAVAL CORPORATE AB
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Product launches
  • 14.1.12 CORNING INCORPORATED
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products offered
  • 14.1.13 MANN+HUMMEL
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Deals
  • 14.1.14 SAINT-GOBAIN
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products offered
    • 14.1.14.3 Recent developments
      • 14.1.14.3.1 Product launches
      • 14.1.14.3.2 Expansions
  • 14.1.15 STERIS PLC
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products offered
• 14.2 OTHER PLAYERS
  • 14.2.1 MEISSNER FILTRATION PRODUCTS, INC.
  • 14.2.2 AMAZON FILTERS LTD.
  • 14.2.3 GRAVER TECHNOLOGIES, LLC.
  • 14.2.4 MMS AG
  • 14.2.5 ERTELALSOP
  • 14.2.6 KASAG SWISS AG
  • 14.2.7 FREUDENBERG FILTRATION TECHNOLOGIES SE & CO. KG
  • 14.2.8 COLE-PARMER INSTRUMENT COMPANY, LLC
  • 14.2.9 FILTROX AG
  • 14.2.10 MEMBRANE SOLUTIONS

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS